Chemogenomic Discovery of Novel Transcriptional Regulators Using Secondary Structure Templated Libraries

Friday, May 12, 2006 Print


To purchase a DVD containing all of the presentations featured at Diversity Oriented Synthesis 2005, please go to the Select Biosciences website.


Click here to launch presentation





Abstract
Utilizing focused libraries of small molecules built around templates designed to mimic secondary structure elements in peptides and proteins, we have successfully discovered selective transcriptional regulators. Affinity probes based on these lead compounds were used to identify the molecular targets of the inhibitor.

The molecular targets were subsequently verified by a variety of techniques (i.e. binding studies, overexpression, siRNA). These compounds are proving to be valuable as tools for further understanding the biology of these systems and as leads for drug development.

About the Speaker
Michael Kahn, Ph.D.: Is the Scientific Director of the newly established Institute for Chemical Genomics (ICG) and Research Associate Professor of Pathobiology, University of Washington, Seattle, WA. Dr. Kahn was trained as a synthetic chemist and is an expert in the design and developing of small molecule therapeutics.

Dr. Kahn received his doctorate from Yale University (New Haven, CT) and completed his post-doctoral research as an NIH fellow at Columbia University with Professor Gilbert Stork. Subsequently, Dr. Kahn has continuously held academic positions at the University of Illinois (Chicago, IL, 1985-1992) and the University of Washington (Seattle, WA,1992-present).

In 1992, Dr. Kahn was the scientific founder of Molecumetics (Bellevue, WA), and served as Chief Scientific Officer from 1994-2000. Dr. Kahn then joined the Pacific Northwest Research Institute. He left PNRI in May of 2004 and moved his lab to ICG. He has been a consultant to Asahi Chemical Corporation (Japan) since 1995, and Choong Wae Pharma Corporation (Korea) since 1998.

Dr. Kahn serves on the editorial board of several scientific journals focused on advances in medicinal chemistry and development of investigational drugs. Dr. Kahn is the recipient of a number of scientific merit awards, and has published in excess of 70 articles and book chapters, and has been awarded ~20 U.S. patents.